The ANKRD44 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population with targeted disruption of the ANKRD44 gene. This heterogeneous pool of gene-edited A-549 cells avoids clonal artifacts and faithfully recapitulates tumor heterogeneity, providing a robust loss-of-function model for scaffold protein studies.
Derived from the A-549 human lung adenocarcinoma epithelial cell line, these knockout cells retain the parental line??s disease-relevant features, including KRAS G12S mutation and epithelial morphology. A-549 is a standard in vitro model for lung adenocarcinoma research, enabling investigation of oncogenic signaling, apoptosis, and drug responses.
ANKRD44 is a scaffold protein that orchestrates IKK complex assembly, comprising IKK??, IKK??, and NEMO. Upon stimulation by TNF??, IL-1??, or LPS, ANKRD44 facilitates IKK-mediated phosphorylation and degradation of I??B??, releasing NF-??B p65/p50 for nuclear translocation. Active NF-??B induces transcription of target genes such as IL6, TNF, and BCL2, which govern proliferation and survival. CRISPR/Cas9-mediated disruption of ANKRD44 abrogates this scaffolding function, blunting stimulus-dependent NF-??B activation and downregulating downstream effectors.
In A-549 lung adenocarcinoma cells, ANKRD44 knockout disrupts a key node in NF-??B signaling, which is often constitutively active in this cancer. Loss of ANKRD44 diminishes IKK complex formation, reduces NF-??B transcriptional output, and impairs expression of pro?survival and proliferative factors. Consequently, knockout cells exhibit increased susceptibility to apoptosis and attenuated growth, making them a valuable tool for dissecting the contributions of ANKRD44 to tumor cell fitness and inflammation-driven lung cancer progression.
Research applications include NF-??B luciferase reporter assays, Western blot analysis of phospho?I??B?? and total I??B??, and RT?qPCR quantification of NF???B target genes. Additional uses encompass cell viability (MTT) and apoptosis (Annexin V) assays, as well as co?immunoprecipitation of IKK complex components. The polyclonal knockout cells are particularly suited for drug resistance studies exploring how NF???B pathway attenuation affects chemosensitivity. For further information, please contact Ascent Research.
